Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Mucositis 4Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Thrombocytopenia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neutropenia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Graft vs Host Disease 1Cytopenia 1Anemia 1

Interventions

Methotrexate 6ruxolitinib 4ibrutinib 4Mycophenolic Acid 3Cyclosporine 3Transplantation Conditioning 2Tacrolimus 2Sirolimus 2Prednisone 2Methylprednisolone 2Cyclophosphamide 2Calcineurin Inhibitors 2thymoglobulin 1siplizumab 1remestemcel-l 1milatuzumab 1itacitinib 1eritoran 1axatilimab 1angiotensin I (1-7) 1Saline Solution 1Rituximab 1Radiotherapy 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1Panobinostat 1KRN 7000 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Graft vs Host Disease × angiotensin I (1-7) × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡